Global Dengue Treatment Market
Global dengue treatment market is expected to reach USD 2,121.43 million by 2031, from USD 878.54 million in 2023 growing at the CAGR of 11.6% in the forecast period of 2024 to 2031.
Market Segmentation: Global Dengue Treatment Market, By Strains (DENV-2, DENV-3, DENV-1, DENV-4, and Others), Type (Vaccines and Acetaminophen), Severity (Mild to Moderate Dengue and Severe Dengue), Route of Administration (Parenteral and Oral), Mode of Purchase (Prescription and Over-the-Counter (OTC)), Gender (Male and Female), Age (Adult, Pediatric, and Geriatric), End User (Hospital, Specialty Clinics, Home Healthcare, and Others), Distribution Channel (Retail Pharmacies, Hospital Pharmacies, and Online Pharmacies), By Countries (U.S., Canada, Mexico, Germany, U.K., Italy, France, Spain, Russia, Switzerland, Turkey, Belgium, Netherlands, Rest of Europe, Japan, China, South Korea, India, Singapore, Thailand, Indonesia, Malaysia, Philippines, Australia, Rest of Asia-Pacific, Brazil, Argentina, Rest of South America, South Africa, Egypt, Saudi Arabia, U.A.E., Israel, and Rest of Middle East and Africa) - Industry Trends and Forecast to 2031
Overview of Global Dengue treatment Market Dynamics:Driver
• Rising dengue incidence rate result in the demand for effective treatment
Restrain
• Delay in the approval process of vaccines
Opportunity
• Growing number of pipeline vaccines for dengue treatment
Market Players:The key market players operating in the global dengue treatment market are listed below:• Sanofi
• Takeda Pharmaceutical Company Limited
• Viatris Inc.
• Johnson & Johnson
• GSK plc.
• Perrigo Company PLC
• Baxter
• Fresenius Kabi USA
• Pfizer
• Hikma Pharmaceuticals PLC
• Sun Pharmaceutical Industries Ltd
• Teva Pharmaceuticals USA, Inc.
• Aurobindo Pharma
Please note:The single user license is non-downloadable and non-printable. Global Site license allows these actions.